Analyst Reco. Sensei Biotherapeutics, Inc.

Equities

SNSE

US81728A1088

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
1.79 ^USD	+8.48%		+75.49%	+158.67%

24/04	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	CI
04/04	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Initiates Sensei Biotherapeutics With Buy Rating, Price Target is $4	04/12	MT
Citigroup Initiates Sensei Biotherapeutics at Buy Rating	13/22/13	MT
SENSEI BIOTHERAPEUTICS : Mixed Q3; but cash cushion remains intact	10/22/10
Oppenheimer Upgrades Sensei Biotherapeutics to Outperform From Perform; Price Target is $5	03/22/03	MT
SENSEI BIOTHERAPEUTICS : Decent Q2; aided further by improving sentiment for Biotechs	10/22/10
Factoring in recent change of priorities (Sensei Biotherapeutics)	17/22/17	AL
Investment continues amidst various market challenges (Sensei Biotherapeutics)	13/22/13	AL
SENSEI BIOTHERAPEUTICS : Investment continues amidst various market challenges	13/22/13
Berenberg Bank Adjusts Sensei Biotherapeutics Price Target to $6 From $12, Maintains Hold Rating	01/22/01	MT
SENSEI BIOTHERAPEUTICS : Market sentiment continues to outweigh on-track clinical progress	14/22/14
Piper Sandler Adjusts Sensei Biotherapeutics' Price Target to $10 from $12, Keeps Overweight Rating	10/22/10	MT
Berenberg US CEO Virtual Conference	09/21/09	FA
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021	03/21/03	AQ
SENSEI BIOTHERAPEUTICS : After SNS-301 setback, focus shifts to other programmes	09/21/09
SENSEI BIOTHERAPEUTICS : Piper Sandler Adjusts Price Target on Sensei Biotherapeutics to $12 From $25, Maintains Overweight Rating	06/21/06	MT
SENSEI BIOTHERAPEUTICS : SNS-301 programme scrapping casts major uncertainty	02/21/02
SENSEI BIOTHERAPEUTICS : Berenberg Downgrades Sensei Biotherapeutics to Hold from Buy, Sets $12 Price Target	01/21/01	MT
SENSEI BIOTHERAPEUTICS : Oppenheimer Downgrades Sensei Biotherapeutics to Perform From Outperform, Removes $36 PT	29/21/29	MT
SENSEI BIOTHERAPEUTICS : Citigroup Adjusts Price Target on Sensei Biotherapeutics to $14 From $30, Reiterates Buy Rating	29/21/29	MT
SENSEI BIOTHERAPEUTICS : After a reassuring Q1, focus shifts to phase I/II trial readout of SNS-301	14/21/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SENSEI BIOTHERAPEUTICS : Mixed Q3; but cash cushion remains intact

November 10, 2022 at 05:29 pm IST